[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Paiva MB, Saxton RE, Blackwell KE, Buechler P, Cohen A, Liu CD, Calcaterra TC, Ward PH, Castro DJ: Combined cisplatinum and laser thermal therapy for palliation of recurrent head and neck tumors. Diagn Ther Endosc; 2000;6(3):133-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined cisplatinum and laser thermal therapy for palliation of recurrent head and neck tumors.
  • In recent years endoscopically controlled laser-induced thermal therapy (LITT) has been increasingly accepted as a minimally invasive method for palliation of advanced or recurrent head and neck or gastrointestinal cancer.
  • Previous studies have shown that adjuvant chemotherapy can potentiate endoscopic laser thermal ablation of obstructing tumors leading to improved palliation in advanced cancer patients.
  • Eight patients with recurrent head and neck tumors volunteered to enroll as part of an ongoing phase II LITT clinical trial, and also elected to be treated with systemic chemotherapy (cisplatin, 80 mg/m(2)) followed 24 h later by palliative laser thermal ablation.
  • Laser treatments were repeated in patients with residual disease or recurrence for a total of 27 LITT sessions.
  • Four of the 8 patients treated with laser thermal chemotherapy remained alive after a median follow-up of 12 months.
  • Of the 12 tumor sites treated, complete responses were located in the oral cavity (3), oropharynx (1), hypopharynx (1), maxillary sinus (1), and median survival for these patients was 9.5 months.
  • This initial experience with cisplatinum-based laser chemotherapy indicates both safety and therapeutic potential for palliation of advanced head and neck cancer but this must be confirmed by longer follow-up in a larger cohort of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18493516.001).
  • [ISSN] 1070-3608
  • [Journal-full-title] Diagnostic and therapeutic endoscopy
  • [ISO-abbreviation] Diagn Ther Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2362744
  •  go-up   go-down


2. Argiris A, Li Y, Forastiere A: Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer; 2004 Nov 15;101(10):2222-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
  • BACKGROUND: The current study was conducted to identify prognostic factors and report the characteristics of long-term survivors in patients with recurrent or metastatic carcinoma of the head and neck who were treated with cisplatin-based combination chemotherapy in two randomized, Phase III trials conducted by the Eastern Oncology Cooperative Group (ECOG) (E1393 and E1395).
  • On multivariate analysis, the following were found to be independent unfavorable predictors of objective response: weight loss of > 5%, an ECOG performance status of 1 (vs. 0), residual disease at the primary tumor site, a primary tumor site other than the oropharynx, prior radiation therapy (RT) (P = 0.056), and well/moderate tumor cell differentiation (P = 0.067).
  • Independent unfavorable prognostic factors for OS were weight loss, an ECOG performance status of 1 (vs. 0), well/moderate tumor cell differentiation, a primary tumor in the oral cavity or hypopharynx, and prior RT.
  • The following were found to be independent unfavorable prognostic factors for time to disease progression: well/moderate tumor cell differentiation, a oral cavity or hypopharyngeal primary tumor, and prior RT.
  • Two-year survivors were more likely to have achieved an objective response to chemotherapy, have poor tumor cell differentiation, be white, have an ECOG performance status of 0, and have received no prior RT.
  • CONCLUSIONS: Clinical parameters and tumor cell differentiation appear to be strong pretreatment predictors of outcome in patients with carcinoma of the head and neck and should be considered in the design of future randomized trials.
  • A small percentage of patients with recurrent head and neck carcinoma can achieve long-term survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Disease Progression. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Paclitaxel / therapeutic use. Prognosis. Randomized Controlled Trials as Topic. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society
  • (PMID = 15452834.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Studer G, Graetz KW, Glanzmann C: Outcome in recurrent head neck cancer treated with salvage-IMRT. Radiat Oncol; 2008;3:43
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome in recurrent head neck cancer treated with salvage-IMRT.
  • BACKGROUND: Recurrent head neck cancer (rHNC) is a known unfavourable prognostic condition.The purpose of this work was to analyse our rHNC subgroup treated with salvage-intensity modulated radiation therapy (IMRT) for curable recurrence after initial surgery alone.
  • 41% underwent definitive, 59% postoperative IMRT (66-72.6 Gy).
  • 70% had simultaneous chemotherapy.
  • Risk factors and the presence of macroscopic recurrence gross tumor volume (rGTV) in oral cavity patients vs others resulted in statistically significantly lower DSS (30 vs 70% at 2 years, p = 0.03).
  • With respect to the assessed unfavourable outcome following salvage treatment, numbers needed to treat to avoid one recurrence with initial postoperative IMRT have, in addition, been calculated.
  • Calculated numbers of patients needed to treat with postoperative radiation after initial surgery, in order to avoid recurrence and tumor-specific death, suggest a rather generous use of adjuvant irradiation, usually with simultaneous chemotherapy.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Salvage Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Jan;22(1):34-41 [10585603.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 2 Suppl 93):1-18 [10714711.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jan;128(1):58-62 [11784256.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):12-22 [12007936.001]
  • [Cites] Oral Dis. 2003 May;9(3):112-8 [12945592.001]
  • [Cites] World J Surg. 2003 Jul;27(7):832-7 [14509515.001]
  • [Cites] Head Neck. 2003 Nov;25(11):953-9 [14603456.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):35-8 [14732765.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):28-42 [15093896.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):43-50 [15093897.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 May;118(5):483-5 [1571116.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):297-302 [9308931.001]
  • [Cites] Head Neck. 1999 Sep;21(6):554-9 [10449672.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73 [15925451.001]
  • [Cites] Strahlenther Onkol. 2006 May;182(5):283-8 [16673062.001]
  • [Cites] Strahlenther Onkol. 2006 Jun;182(6):331-5 [16703288.001]
  • [Cites] Radiat Oncol. 2006;1:7 [16722599.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Sep;64(9):1409-14 [16916677.001]
  • [Cites] Oral Oncol. 2006 Sep;42(8):789-94 [16455287.001]
  • [Cites] Radiat Oncol. 2006;1:40 [17052346.001]
  • [Cites] Head Neck. 2007 Jan;29(1):3-11 [17103411.001]
  • [Cites] Acta Oncol. 2007;46(3):386-94 [17450476.001]
  • [Cites] Radiat Oncol. 2007;2:16 [17430599.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):396-402 [17321069.001]
  • [Cites] Laryngoscope. 2007 Jun;117(6):1019-23 [17545864.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1583-4 [17674994.001]
  • [Cites] Strahlenther Onkol. 2007 Aug;183(8):417-23; discussion 424-5 [17680220.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1066-75 [18246535.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Mar;8(3):375-91 [18366286.001]
  • (PMID = 19091097.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2621229
  •  go-up   go-down


Advertisement
4. Sher DJ, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB: Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer; 2010 Oct 15;116(20):4761-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
  • BACKGROUND: Patients with locally recurrent squamous cell cancer of the head and neck (SCCHN) are reported to have a poor prognosis and limited therapeutic options.
  • This study reported the experience of the Dana-Farber Cancer Institute (DFCI) with IMRT-based chemoradiotherapy with or without surgery for locally recurrent SCCHN.
  • METHODS: The current study was a retrospective study of all patients treated at DFCI who were diagnosed with nonmetastatic second primary or recurrent SCCHN and who received reirradiation based on IMRT.
  • Recurrent disease was treated in the oral cavity (4 patients), larynx/hypopharynx (13 patients), oropharynx (7 patients), nasopharynx (2 patients), and neck (9 patients).
  • The median radiation dose was 60 Gray (Gy), and all patients received concurrent chemotherapy.
  • Approximately 91% and 46%, respectively, of all patients developed at least 1 acute and late grade 3 toxicity.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Neoplasms, Second Primary / radiotherapy. Radiotherapy, Intensity-Modulated
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Retreatment. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • (PMID = 20572036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Lee N, Chan K, Bekelman JE, Zhung J, Mechalakos J, Narayana A, Wolden S, Venkatraman ES, Pfister D, Kraus D, Shah J, Zelefsky MJ: Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):731-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage re-irradiation for recurrent head and neck cancer.
  • PURPOSE: To present a retrospective review of treatment outcomes for recurrent head and neck (HN) cancer patients treated with re-irradiation (re-RT) at a single medical center.
  • METHODS AND MATERIALS: From July 1996-September 2005, 105 patients with recurrent HN cancer underwent re-RT at our institution.
  • Sites included were: the neck (n = 21), nasopharynx (n = 21), paranasal sinus (n = 18), oropharynx (n = 16), oral cavity (n = 9), larynx (n = 10), parotid (n = 6), and hypopharynx (n = 4).
  • The median prior RT dose was 62 Gy.
  • Seventy-five patients received chemotherapy with their re-RT (platinum-based in the majority of cases).
  • The median re-RT dose was 59.4 Gy.
  • In 74 (70%), re-RT utilized intensity-modulated radiation therapy (IMRT).
  • Severe Grade 3-4 late complications were observed in 12 patients, with a median time to development of 6 months after re-RT.
  • Future aggressive efforts in maximizing tumor control in the recurrent setting, including dose escalation with IMRT and improved chemotherapy, are warranted.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / mortality. Risk Assessment / methods. Salvage Therapy / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. New York / epidemiology. Prevalence. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1652-3; author reply 1653 [18035224.001]
  • (PMID = 17379449.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Kostrzewa JP, Lancaster WP, Iseli TA, Desmond RA, Carroll WR, Rosenthal EL: Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. Laryngoscope; 2010 Feb;120(2):267-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer.
  • OBJECTIVES/HYPOTHESIS: To evaluate outcomes of salvage surgery with free flap reconstruction for recurrent squamous cell carcinoma of the oropharynx and oral cavity with increased use of chemoradiotherapy.
  • METHODS: All patients undergoing salvage surgery with free flap reconstruction for oropharynx (n = 36) and oral cavity (n = 36) squamous cell carcinomas between January 2001 and January 2008 were obtained.
  • RESULTS: Complications were more frequent in oropharynx than oral cavity tumors (36% and 14%, respectively; P = .05) requiring more secondary procedures (15 for oropharynx vs. six for oral cavity).
  • Median survival overall following salvage surgery was 44.8 months for oral cavity and 53.8 months for oropharynx head and neck squamous cell carcinoma.
  • CONCLUSIONS: Salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal tumors after chemoradiotherapy has acceptable morbidity and similar cure rates as salvage following radiotherapy without chemotherapy.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2007 Jan;29(1):26-32 [17103406.001]
  • [Cites] Head Neck. 2006 Feb;28(2):107-13 [16388526.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jan;136(1):98-103 [17210342.001]
  • [Cites] Laryngoscope. 2007 May;117(5):781-4 [17473668.001]
  • [Cites] Head Neck. 2008 Mar;30(3):281-8 [17764087.001]
  • [Cites] Head Neck. 2008 Nov;30(11):1422-30 [18767179.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Laryngoscope. 2000 Mar;110(3 Pt 2 Suppl 93):1-18 [10714711.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5518-23 [18936479.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1998;10(3):155-60 [9704176.001]
  • [Cites] Laryngoscope. 2005 Apr;115(4):629-39 [15805872.001]
  • [Cites] Cancer. 2005 May 15;103(10):2073-81 [15816049.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3562-7 [15908667.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):615-9 [16027285.001]
  • [Cites] Am J Clin Oncol. 2005 Aug;28(4):385-92 [16062081.001]
  • [Cites] Laryngoscope. 2007 Jan;117(1):16-21 [17202924.001]
  • (PMID = 20013840.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA142637; None / None / / R01 CA142637-02; United States / NCI NIH HHS / CA / R01 CA142637-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS258253; NLM/ PMC3389788
  •  go-up   go-down


7. Galetta D, Giotta F, Rosati G, Gebbia V, Manzione L, Di Bisceglie M, Borsellino N, Colucci G: Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.). Anticancer Res; 2005 Nov-Dec;25(6C):4445-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).
  • BACKGROUND: The combination of cisplatin (CDDP) and 5-Fluorouracil (5-FU) is a standard regimen for the treatment of recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
  • This combination shows a relevant toxicity and new chemotherapy associations with a more favourable toxicity profile are awaited.
  • Raltitrexed (R) is a potent and specific thymidylate synthase inhibitor with activity comparable to that of 5-FU in colorectal cancer; moreover, it showed activity as a single agent in HNSCC.
  • MATERIALS AND METHODS: Since 2001, a multicentre, phase II trial has been underway to evaluate the efficacy and toxicity of the CB+R combination in untreated patients with recurrent or metastatic HNSCC.
  • Patients had a histo/cytologically proven recurrent or metastatic HNSCC; patients with locally advanced disease not amenable to CDDP+5-FU treatment were also included.
  • Twelve patients were staged III and 20 were metastatic (10 recurrent).
  • The oral cavity/oropharynx were the primary site in 20 patients and the larynx in 10 patients.
  • The median time to progression was 4.2 months and median duration of survival was 9.8 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334124.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Thiophenes; BG3F62OND5 / Carboplatin; FCB9EGG971 / raltitrexed
  •  go-up   go-down


8. Mesía R, Palmero R, Cos M, Vilajosana E, Vázquez S: Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report. Head Neck Oncol; 2010;2:3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.
  • BACKGROUND: Symptom control is an important consideration in the choice of treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
  • Patients who demonstrate objective tumour responses to platinum-based chemotherapy are more likely to have symptom relief than those who do not have such responses.
  • A phase III trial (EXTREME) showed that adding the epidermal growth factor receptor (EGFR)-targeting IgG1 monoclonal antibody cetuximab to first-line platinum-based chemotherapy significantly prolongs progression-free and overall survival and increases response rate compared with platinum-based chemotherapy alone.
  • We report here the case of a 60-year old female with recurrent squamous cell carcinoma of the gum who had rapid palliation of symptoms and reduction of facial disease mass following treatment with a combination of carboplatin/5-fluorouracil (5-FU) and cetuximab.
  • CASE PRESENTATION: The patient was diagnosed with T4N0 M0 disease of the oral cavity in November 2006 and underwent surgery, with R0 resection, followed by adjuvant radiotherapy and concomitant cisplatin chemotherapy.
  • The patient received 4 21-day cycles of carboplatin (AUC 5), 5-FU (1,000 mg/m2/day for 4 days) and cetuximab (400 mg/m2 initial dose followed by subsequently weekly doses of 250 mg/m2), with continuation of cetuximab monotherapy at the end of this time, and pain relief with topical fentanyl and oral morphine.
  • After 7 days of treatment, pain had reduced to 2/10, with discontinuation of morphine after 4 days, and the facial mass had reduced to 70 mm.
  • After 2 cycles of treatment, the facial mass had decreased to 40 mm.
  • After 3 cycles of treatment, pain and facial oedema had resolved completely and a cervical computed tomography scan showed a marked reduction in tumour mass.
  • CONCLUSION: This case illustrates the rapid reduction of tumour mass and disease-associated pain and oedema that can be achieved with a combination of platinum-based chemotherapy and cetuximab in recurrent and/or metastatic SCCHN.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2653-8 [16763279.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3562-7 [15908667.001]
  • [Cites] Ann Oncol. 1997 May;8(5):445-9 [9233523.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1135-41 [8758243.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • (PMID = 20181021.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; BG3F62OND5 / Carboplatin; PQX0D8J21J / Cetuximab; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2832769
  • [General-notes] NLM/ Original DateCompleted: 20100629
  •  go-up   go-down


9. Kubota A, Furukawa M, Kawano T, Komatsu M: [Nedaplatin for recurrent cancer of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2004 May;107(5):475-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nedaplatin for recurrent cancer of the head and neck].
  • This study was undertaken to evaluate the clinical efficacy and toxicity of Nedaplatin (254-S) alone or combined for UFT for recurrent head and neck cancers in an outpatient setting.
  • Thirty-two patients, previously treated, (30 men and 2 women, mean age 59 years, twenty one with loco-regional recurrence and 11 with distant metastasis, 29 with squamous cell carcinoma, 2 with adenocarcinoma and one with adenoid cystic carcinoma) were treated with Nedaplatin (254-S) alone or combined with UFT.
  • The primary site was identified in the oropharynx in 8 patients, oral cavity in 7, larynx in 5, nasopharynx in 4, hypopharynx in 3, sinuses in one, parotid in one, and unknown primary in one patient.
  • The 254-S administration was repeated at 4 week intervals, and in some patients was combined with daily oral administration of 400 mg of UFT-E (tegafur-uracil enterogranules).
  • Treatment with 254-S alone or combined UFT-E could be conducted in an outpatient setting and was able to improve the overall survival rate for recurrent head and neck cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Adenoid Cystic / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Middle Aged. Survival Rate. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15198007.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 8UQ3W6JXAN / nedaplatin; 1-UFT protocol
  •  go-up   go-down


10. Agra IM, Carvalho AL, Ulbrich FS, de Campos OD, Martins EP, Magrin J, Kowalski LP: Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck; 2006 Feb;28(2):107-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer.
  • BACKGROUND: Therapeutic decisions in recurrent oral and oropharyngeal squamous carcinoma (SCC) remain controversial.
  • METHODS: Two hundred forty-six consecutive patients who underwent salvage surgery for recurrent squamous cell carcinoma (SCC) of the oral cavity and oropharynx were studied.
  • The tumor sites were lip, 33 cases; oral cavity, 143; oropharynx, 70.
  • The previous treatment was surgery in 73 patients, radiotherapy in 96, combined surgery and radiotherapy in 76, and chemotherapy in one.
  • CONCLUSION: Patients with recurrent oral and oropharyngeal SCC at initial clinical stages (rCS I and II) and with a DFI greater than 1 year had a favorable prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Oropharyngeal Neoplasms / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc.
  • (PMID = 16388526.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Ariyoshi Y, Miyatake S, Kimura Y, Shimahara T, Kawabata S, Nagata K, Suzuki M, Maruhashi A, Ono K, Shimahara M: Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep; 2007 Oct;18(4):861-6
Hazardous Substances Data Bank. BORON COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis.
  • The purpose of this clinical trial was to evaluate the utility of boron neutron capture therapy (BNCT) using epithermal neutrons for cases of recurrent cancer in the oral cavity, which are not indicated for a conventional treatment modality.
  • We enrolled four patients with local recurrence or metastasis to the regional lymph nodes after completion of initial treatments, including surgery, chemotherapy and radiotherapy.
  • Before receiving BNCT, patients underwent 18F-p-bononophenylalanine (BPA) positron emission tomography (PET) examinations to assess the BPA accumulation ratios in tumors and normal tissues.
  • Before BNCT, that patient could not be discharged from the hospital because of eating difficulties and malaise; after treatment, he was comfortably discharged.
  • Mild malaise, oral mucositis and alopecia were seen as mild adverse effects; however, no life-threatening systemic symptoms were observed in any of the cases.
  • Our results suggested that BNCT is a useful treatment modality for recurrent or regionally metastasized oral cancer.
  • [MeSH-major] Boron Neutron Capture Therapy / methods. Mouth Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Neutrons
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Boron Compounds / therapeutic use. Carcinoma, Mucoepidermoid / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Head and Neck Neoplasms / radiotherapy. Humans. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786347.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Boron Compounds
  •  go-up   go-down


12. Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ: Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck. Semin Radiat Oncol; 2004 Apr;14(2):190-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck.
  • Despite advances in our ability to safely treat patients with recurrent cancer of the upper aerodigestive tract, outcomes for retreatment are generally poor and the first chance to cure these patients remains the best chance.
  • Thorough knowledge of the outlook and options for patients with recurrent disease is also of significance in choosing therapy for patients with newly diagnosed disease.
  • This is especially true for newly diagnosed patients making the choice between surgery and nonsurgical ("organ-sparing") options, who need to know the outlook for salvage surgery, should they recur after radiation with or without concomitant chemotherapy.
  • Salvage surgery is generally the best option for previously irradiated patients who are faced with resectable, recurrent disease.
  • Unfortunately, the results of surgical salvage are generally poor for patients with advanced stage recurrence and for those who recur after treatment of advanced disease.
  • The site of initial and recurrent disease is important.
  • Surgical salvage is most effective for patients with recurrent laryngeal cancer, least effective for recurrent cancer of the pharynx, and is intermediate for recurrence in the oral cavity.
  • Patients choosing nonsurgical treatment for newly diagnosed cancer of the pharynx cannot rely on salvage surgery in the event of recurrence.
  • Reirraditation for patients who have failed initial treatment that included radiation therapy has been used at a number of institutions with some success.
  • Experience using reirradiation with or without concomitant chemotherapy continues to evolve.
  • Palliative chemotherapy is an option for most patients, but response rates are generally poor and of short duration, after failure of initial treatment that includes radiation therapy.
  • The best approach for many patients and families who face advanced recurrent disease is honest but compassionate communication and supportive care with the help of a hospice organization.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Humans. Retreatment / methods. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15095264.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


13. Langer CJ, Harris J, Horwitz E, Nicolaou N, Kies M, Curran W, Wong S, Ang KK: Phase II trial of concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): Results of RTOG 9911. J Clin Oncol; 2004 Jul 15;22(14_suppl):5509

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): Results of RTOG 9911.
  • : 5509 Background: Recurrent SCCHN, if not curable by surgery or RT, is almost always fatal.
  • Chemotherapy (CTx) alone (eg.
  • DDP, 5FU) yields median survival times (MST) of 8-10 mos and 1 yr survival (OS) of ≤ 35% at best.
  • METHODS: Eligibility stipulated recurrent SCCHN or second 1° tumors (SPT) in a previous RT field; measurable tumor; ≥ 75% of tumor volume previously treated to 45 Gy-75 Gy; ≥ 6 mos elapsed from prior RT, ECOG PS 0-1; ANC ≥1500, plts ≥ 100K, bili ≤1.5 mg/dl, creat ≤ 1.5 mg/dl, and absence of distant mets.
  • Pts received HFx RT (1.5 Gy/Fx BID x 5d every 2 wks x 4), in combination with DDP 15 mg/m<sup>2</sup> IV QD x 5 and P 20 mg/m<sup>2</sup> IV QD x 5 q 2 wks x 4.
  • 22% had SPTs. Oropharynx (37%) and oral cavity (32%) were the predominant 1° sites.
  • Median prior RT dose was 65.4 Gy (range, 45-73 Gy).
  • CONCLUSIONS: Despite a fairly high inc. of Gr 5 tox, 1- and 2-yr OS rates for split course HFxRT/DDP/P exceed results generally seen with chemotherapy alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014195.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Argiris A, Li Y, Forastiere A: Prognostic factors and long-term survivorship in patients with recurrent or metastatic head and neck cancer (HNC): An analysis of two Eastern Cooperative Oncology Group (ECOG) randomized trials. J Clin Oncol; 2004 Jul 15;22(14_suppl):5514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and long-term survivorship in patients with recurrent or metastatic head and neck cancer (HNC): An analysis of two Eastern Cooperative Oncology Group (ECOG) randomized trials.
  • : 5514 Background: The ECOG conducted two successive phase III randomized trials comparing cisplatin-based doublets (E1393: cisplatin/paclitaxel, low dose vs. cisplatin/paclitaxel, high dose, and E1395: cisplatin/paclitaxel vs. cisplatin/5-FU) in patients (pts) with recurrent or metastatic HNC.
  • These studies found no significant differences in antitumor efficacy between treatment arms.
  • On multivariate analysis, independent unfavorable predictors of objective response were weight loss, performance status (PS) of 1 (vs. 0), residual disease at the primary, site other than oropharyngeal, history of radiation therapy (RT) (P=0.06), and well/moderate tumor differentiation (TD) (P=0.07).
  • Independent prognostic factors for OS were weight loss, PS 1 (vs. 0), poor TD (favorable), oral cavity (OC) or hypopharyngeal (HP) primary, and history of RT, and for time to progression (TTP): poor TD (favorable), OC or HP primary, and history of RT.
  • Response to chemotherapy could also be included in the prognostic models of OS and TTP as an independent predictor.
  • 2-y survivors were more likely to have had a response to chemotherapy, poor TD, white race, PS of 0, and no prior RT.
  • Two out of 49 pts surviving at least 2 ys developed a second primary tumor.
  • A small percentage of pts with recurrent or metastatic HNC achieves long-term survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014175.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Diaz de Corcuera I, Serrano C, Pérez J, Quispe I, Arguis M, Muñoz E, Benavente S, Martínez P, Parera M, Del Campo JM: Weekly cetuximab and paclitaxel combination in metastatic/recurrent squamous cell cancer carcinoma of the head and neck (SCCHN): Clinical experience of a single institution. J Clin Oncol; 2009 May 20;27(15_suppl):e17043

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly cetuximab and paclitaxel combination in metastatic/recurrent squamous cell cancer carcinoma of the head and neck (SCCHN): Clinical experience of a single institution.
  • : e17043 Background: Results of a recent phase III randomized study with cetuximab and platin-5FU chemotherapy support its use in recurrent/metastatic SCCHN.
  • METHODS: From our database, we conducted a retrospective study of 20 patients with recurrent SCCHN who did not meet criteria for platin therapy and were treated with weekly P (80 mg/m2) and C (initially 400 mg/m2 followed by 250 mg/m2) until progression or intolerable toxicity.
  • We have collected data regarding previous treatments, response rate (RR), progression free survival (PFS), overall survival (OS) and toxicity.
  • Oral cavity (35%) and oropharynx (25%) were the most frequent locations.
  • Most of the pts (13/20) had been treated with previous chemotherapy combinations (range 1-3 lines).
  • CONCLUSIONS: Our analysis confirms that weekly paclitaxel-cetuximab is an effective and safety combination in metastatic/recurrent SCCHN.
  • Treatment is very well tolerated and could be a good alternative to platin-based chemotherapy in unfit patients for this therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961779.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kasperts N, Slotman B, Leemans CR, Langendijk JA: A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol; 2005 Mar;41(3):225-43
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review on re-irradiation for recurrent and second primary head and neck cancer.
  • The purpose of this paper is to review the results of studies regarding radiation as primary or adjuvant treatment modality for head and neck recurrences or second primary tumours (SPT) in previously irradiated areas, with emphasis on acute and late radiation induced morbidity, locoregional control and survival.
  • (1) re-irradiation for locoregional recurrent disease or SPT in the head and neck region, (2) squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx, and (3) a minimum of 10 patients included in the study.
  • Studies were divided in four categories, including (1) external beam re-irradiation, (2) re-irradiation with brachytherapy, (3) re-irradiation in combination with chemotherapy and (4) postoperative re-irradiation.
  • Most studies were retrospective using heterogeneous treatment regimens and including heterogeneous groups of patients.
  • High dose reirradiation as salvage treatment in case of recurrent or second primary head and neck cancer should be considered, particularly when salvage surgery is not feasible.
  • Although long term survivors are reported is some studies, the relatively high incidence of treatment-related morbidity emphasize the need for further optimisation in order to improve locoregional control and reduce the risk on late morbidity.
  • [MeSH-minor] Brachytherapy. Combined Modality Therapy. Humans. Morbidity. Retreatment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oral Oncol. 2005 Oct;41(9):953-4 [15935725.001]
  • (PMID = 15743686.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 61
  •  go-up   go-down


17. Huang ZL, Li CX, Zhang FJ, Jiao DC, Wu PH, Zhang T, Wang JJ, Duan GF, Wu YX: [Short- to mid-term evaluation of CT-guided 125I brachytherapy on recurrent or metastatic head and neck cancers]. Zhonghua Yi Xue Za Zhi; 2009 Feb 10;89(5):321-4
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Short- to mid-term evaluation of CT-guided 125I brachytherapy on recurrent or metastatic head and neck cancers].
  • OBJECTIVE: to evaluate the short- and medium-term clinical effects of 125I seed implantation on recurrent or metastatic head and neck cancers.
  • METHODS: Thirty patients with recurrent or metastatic head and neck cancers after operation, radiotherapy, or chemotherapy, totaling 421 lesions 4.2 (2-9) cm in diameter, 23 males and 12 females, aged 56 (39-71), underwent implantation of 12-70 125I seeds (on average 33 per person) under the guidance of CT, ultrasonography, or endoscopy with an interval of 1 cm between any 2 seeds with the radioactive activity per seed of 29.6 MBq and matched peripheral dose of 90-160 Gy.
  • The overall 1-, 2-, and 3-year survival rates were 88.4%, 72.4%, and 45.2% respectively with a median survival time of 31 months.
  • The long-term complications included hyperpigmentation at operative sites (n=4), insensible feeling on lateral cheek (n=3), dryness of oral cavity (n=2), and headache combined with infection (n=1).
  • CONCLUSION: Relieving the pain, improving the life quality, CT guided radioactive 125I seed implantation is a simple, safe, and effective method in treating recurrent or metastatic head and neck cancer with minimal damage and few complications.
  • [MeSH-major] Brachytherapy / methods. Head and Neck Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563709.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


18. Sagowski C, Jaehne M, Kehrl W, Hegewisch-Becker S, Wenzel S, Panse J, Nierhaus A: Tumor oxygenation under combined whole-body-hyperthermia and polychemotherapy in a case of recurrent carcinoma of the oral cavity. Eur Arch Otorhinolaryngol; 2002 Jan;259(1):27-31
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor oxygenation under combined whole-body-hyperthermia and polychemotherapy in a case of recurrent carcinoma of the oral cavity.
  • BACKGROUND: Previous studies have reported synergistic effects of combined hyperthermia and chemotherapy and/or irradiation.
  • Tumor response to irradiation and chemotherapy of well-oxygenated and vascularized tumors, in general, is superior to that of hypoxic tumors.
  • Therefore, tumor oxygenation is recognized as an important predictive factor in the therapy of malignant tumors.
  • Technically, the head-neck area remains outside the hyperthermia chamber during whole-body hyperthermia (WBH) as currently applied in a number of cancer treatment regimens.
  • The aim of this therapeutic approach was to evaluate whether the blood flow during WBH also increased in the head-neck region and, if so, whether tumor oxygenation increase accordingly.
  • METHODS: A 60-year-old male Caucasian patient, with the original diagnosis of pT3 pN2b M0 squamous cell carcinoma of the oral cavity, who had undergone primary surgery and irradiation (total dose 60 Gy), developed three local recurrences with consecutive surgical resection, presenting now with another recurrent local tumor (histologically confirmed) without surgical or radiotherapeutical options due to lymphangiosis carcinomatosa.
  • WBH was applied under full anaesthesia, using a humidified radiant heat device (Enthermics Medical Systems RHS-7500) in combination with synchronous application of chemotherapy (ifosfamide and carboplatin).
  • Four cycles of this combined treatment (one cycle per month) were given.
  • Tumor oxygenation and temperature were continuously monitored by Licox catheters by means of one point measurement during each treatment (3.5 h).
  • RESULTS: With a latency of 10 min, the increase of intratumoral temperature in the oral cavity was comparable to reference values in the esophagous.
  • Maximum intratumoral temperature (oral cavity) was 41.8 degrees C (F).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Hyperthermia, Induced. Mouth Neoplasms / therapy. Oxygen / metabolism
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Partial Pressure

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11954922.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


19. Kovács AF, Eberlein K, Hülsmann T: Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus. Oral Maxillofac Surg; 2009 Jun;13(2):87-93
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
  • PURPOSE: Induction chemotherapy with Taxotere, cisplatin, and 5-fluororacil (TPF) was mainly used in hypopharyngeal and laryngeal cancer patients for larynx preservation.
  • This study aimed to assess feasibility and toxicity in oral cavity and maxillary sinus cancer patients.
  • PATIENTS AND METHODS: Between 2003 and 2008, 21 patients (18 male, three female; mean age 58 years; 15 patients Eastern Cooperative Oncology Group > or =1) suffering from advanced squamous cell cancers of the oral cavity (seven primaries, eight locoregional recurrences) and the maxillary sinus (six patients) were prospectively treated with three cycles of TPF (q3w) and were scheduled to undergo definitive chemoradiation.
  • Reasons for incomplete treatment were tumor progression, edema, seizure, bad general condition, sepsis, pneumonia (each once).
  • The infections led to two treatment-related deaths (9.5%).
  • Ten patients underwent a definitive chemoradiation or radiation (47.6%).
  • After a mean observation time of 17 months, nine patients are alive; one of them developed a local recurrence.
  • CONCLUSIONS: Chemotherapy with TPF is a highly effective treatment with considerable toxicity that needs special expertise which is best assured in a multidisciplinary setting.
  • Pretreated recurrent cancers demonstrated bad response.
  • A target for organ preservation could be the maxillary sinus; due to tumor regression in advanced oral tongue cancer, consecutively, a reduced function has to be encountered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Maxillary Sinus Neoplasms / drug therapy. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease Progression. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Opportunistic Infections / etiology. Pilot Projects. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Stomatitis / chemically induced. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2009 May;20(5):921-7 [19179556.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2873-8 [16782926.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):485-8 [12393990.001]
  • [Cites] Mund Kiefer Gesichtschir. 2006 May;10(3):168-77 [16604330.001]
  • [Cites] Oral Oncol. 2006 Aug;42(7):675-84 [16731029.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jun;136(6):1003-9 [17547996.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7 [15145166.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):585-90 [16739325.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):75-85, viii [15649500.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • (PMID = 19430823.001).
  • [ISSN] 1865-1550
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Taxoids; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; TPF protocol
  •  go-up   go-down


20. Sagowski C, Kehrl W, Hegewisch-Becker S, Wenzel S, Jaehne M, Panse J, Nierhaus A: [Tumor oxygenation in combined whole body hyperthermia and polychemotherapy. Studies exemplified by recurrent carcinoma of the mouth cavity]. HNO; 2000 Dec;48(12):949-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumor oxygenation in combined whole body hyperthermia and polychemotherapy. Studies exemplified by recurrent carcinoma of the mouth cavity].
  • BACKGROUND AND OBJECTIVE: Previous studies have reported synergistic effects of combined hyperthermia and chemotherapy and/or irradiation.
  • The response to irradiation and chemotherapy of well-oxygenated and vascularized tumors generally is better than that of hypoxic tumors.
  • Therefore, tumor oxygenation is recognized as an important predictive factor in the therapy of malignant tumors.
  • PATIENTS/METHODS: Whole-body hyperthermia, as heat radiation (Enthermics Medical Systems RHS-7500), was applied to the narcotised 60-year-old male patient with a local recurrence tumor pT3 pN2b M0 squamous cell carcinoma of the oral cavity.
  • Tumor oxygenation and temperature were measured by LICOX catheters via one-point measurement during the entire hyperthermia treatment (3.5 h).
  • Parallelly, chemotherapy (ifosfamide/Carboplatin) was given in four cycles (one cycle/month).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / blood supply. Cell Hypoxia / physiology. Hyperthermia, Induced / instrumentation. Mouth Neoplasms / blood supply. Neoplasm Recurrence, Local / blood supply
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11196098.001).
  • [ISSN] 0017-6192
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K: Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol; 2007 Oct 20;25(30):4800-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
  • PURPOSE: Recurrent squamous cell carcinoma of the head and neck (SCCHN) or new second primary tumor (SPT) in a previous radiation field, if not curable by surgery or radiation, is almost always fatal.
  • Chemotherapy alone yields a median survival time (MST) of no more than 10 months and 1-year overall survival (OS) of 35% at best.
  • Concurrent reirradiation and chemotherapy is an alternative strategy.
  • PATIENTS AND METHODS: Eligibility for Radiation Therapy Oncology Group (RTOG) protocol 9911 stipulated recurrent SCCHN or SPT in a previous radiation field.
  • Patients received twice-daily radiation (1.5 Gy per fraction bid x 5 days every 2 weeks x4), plus cisplatin 15 mg/m2 intravenously (IV) daily x 5 and paclitaxel 20 mg/m2 IV daily x 5 every 2 weeks x4.
  • Oropharynx (40%) and oral cavity (27%) were the predominant primary sites.
  • Median prior radiation dose was 65.4 Gy.
  • Seventy-four percent of patients completed chemotherapy.
  • Eight treatment-related deaths (8%) occurred: five in the acute setting, three late (including two carotid hemorrhages).
  • CONCLUSION: Despite a high incidence of grade 5 toxicity, 1- and 2-year OS rates for split-course bid radiation therapy and concurrent cisplatin/paclitaxel exceed results generally seen with chemotherapy alone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Paclitaxel / administration & dosage. Survival Rate


22. De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, Kaempgen E, Wolff JE, Plets C, Sciot R, Van Gool SW: Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg; 2004 May;100(5 Suppl Pediatrics):492-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report.
  • Treatment of malignant glioma is difficult and discouraging.
  • Even after resection and maximal adjuvant therapy, the prognosis remains poor.
  • The authors sought a novel form of treatment, such as stimulating the patient's own immune response against the tumor, and developed a protocol of tumor vaccination in which autologous dendritic cells (DCs) were used in patients with recurrent malignant glioma.
  • Ten years later, a Grade III recurrence was discovered and treated with subtotal resection, interstitial radiation, six courses of oral temozolomide, and 12 courses of oral VP 16.
  • At the end of the chemotherapy cycle, a new rapidly growing recurrence was diagnosed.
  • The efficacy of immunization was checked by a positive delayed-type hypersensitivity skin reaction after the second injection.
  • Simultaneously, positron emission tomography imaging revealed a transient increase of metabolic activity around the resection cavity, but the metabolic uptake ratio remained below 1.8.
  • This case report illustrates the potential of vaccination with DCs loaded with crude tumor homogenate as adjuvant therapy to induce prolonged tumor control of malignant glioma and the objective noninvasively monitored immune response against infiltrating tumor cells.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Cancer Vaccines / immunology. Dendritic Cells / immunology. Immunotherapy, Active / methods
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Female. Humans. Neoplasm Recurrence, Local. Photomicrography

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15287461.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines
  •  go-up   go-down


23. Agra IM, Carvalho AL, Pontes E, Campos OD, Ulbrich FS, Magrin J, Kowalski LP: Postoperative complications after en bloc salvage surgery for head and neck cancer. Arch Otolaryngol Head Neck Surg; 2003 Dec;129(12):1317-21
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative complications after en bloc salvage surgery for head and neck cancer.
  • OBJECTIVE: To analyze the frequency of and risk factors for postoperative complications after en bloc salvage surgery for head and neck cancer.
  • SETTING: Patients were evaluated from February 7, 1990, to November 17, 1999, in a tertiary cancer center hospital.
  • Only patients with recurrent head and neck squamous cell carcinoma undergoing en bloc salvage resection were eligible for the study.
  • RESULTS: The tumor location was the lip in 6 patients, oral cavity in 55, oropharynx in 31, larynx in 24, and hypopharynx in 8.
  • Previous treatment was surgery alone in 20 patients, radiotherapy alone in 68, surgery and radiotherapy in 21, and radiotherapy and chemotherapy in 14.
  • An additional patient received chemotherapy alone before salvage surgery.
  • The clinical stage of the recurrent tumor was I or II in 23 patients and III or IV in 101 patients.
  • The major factor associated with the overall occurrence of postoperative complications was the clinical stage of the recurrent tumor (P =.02).
  • The occurrence of minor complications correlated with the previously treated site, with complications occurring more often in patients undergoing locoregional vs local treatment (P =.04).
  • Major complications were associated with the time between initial treatment and salvage surgery (P =.05).
  • The clinical stage of the recurrent tumor and the previous site treated were the 2 major factors associated with the occurrence of postoperative complications.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Salvage Therapy / adverse effects
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Length of Stay / statistics & numerical data. Logistic Models. Male. Middle Aged. Morbidity. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14676158.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. May SA, Jones D, Medeiros LJ, Duvic M, Prieto VG, Lazar AJ: Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patients. Am J Dermatopathol; 2007 Feb;29(1):62-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patients.
  • We describe two slowly progressive cases of T-cell lymphoma that involved both acral skin and oral cavity.
  • One patient presented with a tongue nodule, completely responded to chemotherapy and then developed recurrent lymphoma involving tongue and skin a few months later that also responded to therapy.
  • The second patient presented with a skin nodule that spontaneously resolved without therapy, and subsequently recurred in tongue and skin a few years later.
  • In both cases, the neoplasms were composed of atypical lymphoid cells with epidermotropism and were of T-helper cell lineage (CD4+).
  • Identical T-cell receptor gene rearrangements were detected in the initial and recurrent lesions of one case.
  • These cases are strikingly similar, and may represent an unusual clinicopathologic type of T-cell lymphoma that can hone to cutaneous and oral mucosal sites with a slowly progressive natural history.
  • [MeSH-major] CD4-Positive T-Lymphocytes / pathology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Mouth Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Disease Progression. Female. Fingers / pathology. Humans. Male. Mouth Mucosa / pathology. Mycosis Fungoides / diagnosis. Mycosis Fungoides / pathology. Skin / pathology. Tongue / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17284964.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kohno N, Kitahara S: [Chemotherapy for head and neck cancer]. Gan To Kagaku Ryoho; 2000 Feb;27(2):177-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for head and neck cancer].
  • Chemotherapy for head and neck cancer was initially used as a palliative treatment in advanced and/or recurrent disease.
  • In a large number of randomized trials, organ function preservation studies have shown the possibility of laryngeal preservation for T2 and T3 laryngeal and hypopharyngeal cancer.
  • A survival benefit has been shown clearly in advanced nasopharyngeal cancer.
  • Another survival prolongation has been demonstrated in cases of locally unresectable cancer in the oral cavity, pharynx, nose and paranasal sinus.
  • Thus, we conclude that neoadjuvant chemotherapy can be effective in cases of locally unresectable cancer in the oral cavity, pharynx, and nose and paranasal sinus.
  • In advanced N stage nasopharyngeal cancer, neoadjuvant chemotherapy plus adjuvant chemotherapy may be indicated.
  • Advanced T stage nasopharyngeal cancer is a good candidate for concurrent chemoradiotherapy.
  • For the aim of laryngeal preservation, neoadjuvant and/or concurrent chemoradiotherapy can be indicated for T2 and T3 laryngeal and hypopharyngeal cancer.
  • [MeSH-major] Evidence-Based Medicine. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Palliative Care. Randomized Controlled Trials as Topic. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10700887.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 21
  •  go-up   go-down


26. Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group: Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer. Curr Oncol; 2010 Jun;17(3):37-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
  • QUESTION: What are the benefits associated with the use of anti-epidermal growth factor receptor (anti-EGFR) therapies in squamous cell carcinoma of the head and neck (HNSCC)?
  • Anti-EGFR therapies of interest included cetuximab, gefitinib, lapatinib, zalutumumab, erlotinib, and panitumumab.
  • PERSPECTIVES: Head-and-neck cancer includes malignant tumours arising from a variety of sites in the upper aerodigestive tract.
  • The most common histologic type is squamous cell carcinoma, and most common sites are the oral cavity, the oropharynx, the hypopharynx, and the larynx.
  • Worldwide, HNSCC is the sixth most common neoplasm, and despite advances in therapy, long-term survival in HNSCC patients is poor.
  • Primary surgery followed by chemoradiation, or primary chemoradiation, are the standard treatment options for patients with locally advanced (stages III-IVB) HNSCC; however, meta-analytic data indicate that the benefit of concurrent platinum-based chemotherapy disappears in patients over the age of 70 years.
  • Cetuximab is a monoclonal antibody approved for use in combination with radiation in the treatment of patients with untreated locally advanced HNSCC and as monotherapy for patients with recurrent or metastatic (stage IVC) HNSCC who have progressed on platinum-based therapy.
  • Given the interest in anti-EGFR agents in advanced HNSCC, the Head and Neck Cancer Disease Site Group (DSG) of Cancer Care Ontario's Program in Evidence-Based Care (PEBC) chose to systematically review the literature pertaining to this topic so as to develop evidence-based recommendations for treatment.
  • OUTCOMES: Outcomes of interest included overall and progression-free survival, quality of life, tumour response rate and duration, and the toxicity associated with the use of anti-EGFR therapies.
  • The resulting recommendations were approved by the Report Approval Panel of the PEBC, and by the Head and Neck Cancer DSG.
  • The randomized controlled trials (RCTS) involved three distinct patient populations: those with locally advanced HNSCC being treated for cure, those with incurable advanced recurrent or metastatic HNSCC being treated with first-line platinum-based chemotherapy, and those with incurable advanced recurrent or metastatic HNSCC who had disease progression despite, or who were unsuitable for, first-line platinum-based chemotherapy.
  • PRACTICE GUIDELINE: These recommendations apply to adult patients with locally advanced (nonmetastatic stages iii-ivb) or recurrent or metastatic (stage IVC) HNSCC.
  • Platinum-based chemoradiation remains the current standard of care for treatment of locally advanced HNSCC.
  • In patients with locally advanced HNSCC who are medically unsuitable for concurrent platinum based chemotherapy or who are over the age of 70 years (because concurrent chemotherapy does not appear to improve overall survival in this patient population), the addition of cetuximab to radical radiotherapy should be considered to improve overall survival, progression-free survival, and time to local recurrence.Cetuximab in combination with platinum-based combination chemotherapy is superior to chemotherapy alone in patients with recurrent or metastatic HNSCC, and is recommended to improve overall survival, progression-free survival, and response rate.The role of anti-EGFR therapies in the treatment of locally advanced HNSCC is currently under study in large randomized trials, and patients with HNSCC should continue to be offered clinical trials of novel agents aimed at improving outcomes.
  • However, five ongoing trials are investigating the effect of the addition of EGFR inhibitors concurrently with, before, or after chemoradiotherapy; those trials should provide direction about the best integration of cetuximab into standard treatment.
  • In patients with recurrent or metastatic HNSCC who experience progressive disease despite, or who are unsuitable for, first-line platinum-based chemotherapy, gefitinib at doses of 250 mg or 500 mg daily, compared with weekly methotrexate, did not increase median overall survival [hazard ratio (hr): 1.22; 96% confidence interval (ci): 0.95 to 1.57; p = 0.12 (for 250 mg daily vs. weekly methotrexate); hr: 1.12; 95% ci: 0.87 to 1.43; p = 0.39 (for 500 mg daily vs. weekly methotrexate)] or objective response rate (2.7% for 250 mg and 7.6% for 500 mg daily vs. 3.9% for weekly methotrexate, p > 0.05).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1995 Jul;72(1):123-8 [7599040.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1226-31 [9508211.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1796-807 [10974628.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5 Suppl 14):18-30 [12422310.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):555-9 [12566295.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):246-54 [12909240.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 6:vi20-vi24 [15987992.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1085-93 [16050785.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2659-65 [16763280.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):340-2 [16808060.001]
  • [Cites] J Dent Res. 2007 Feb;86(2):104-14 [17251508.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2191-7 [17538164.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4 [17848275.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1116-27 [18784101.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • (PMID = 20567625.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2880902
  • [Keywords] NOTNLM ; Head-and-neck cancer / egfr inhibitors / epidermal growth factor receptor / overall survival / progression-free survival / tumour response rate
  •  go-up   go-down


27. Porceddu SV, Campbell B, Rischin D, Corry J, Weih L, Guerrieri M, Grossi M, Peters LJ: Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys; 2004 Oct 1;60(2):365-73
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma.
  • PURPOSE: To describe the use of postoperative concurrent chemoradiotherapy, with either weekly cisplatin or carboplatin, for high-risk head-and-neck squamous cell carcinoma (HNSCC) in a single institutional setting.
  • The predominant primary site was the oral cavity in 24 patients (51%), 27 had nodal disease with extracapsular extension, and 26 had positive or close mucosal margins (<5 mm).
  • Ten patients had undergone resection of recurrent disease after previous surgery.
  • The median radiotherapy dose was 60 Gy (range, 50-66 Gy).
  • Of the 47 patients, 45 (96%) completed at least four of the six planned doses of chemotherapy and 45 (96%) completed the planned course of radiotherapy.
  • No treatment-related deaths occurred.
  • Five cases of Grade 3-4 late treatment-related sequelae developed.
  • CONCLUSION: Treatment with postoperative concurrent weekly cisplatin or carboplatin and radiotherapy was reasonably well tolerated.
  • Patients treated after resection of recurrent disease (after previous surgery alone) fared worse than those treated at the initial resection.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Confidence Intervals. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neck Dissection. Radiation Injuries / etiology. Radiotherapy Dosage. Regression Analysis. Survival Rate


28. Wutzl A, Ploder O, Kermer C, Millesi W, Ewers R, Klug C: Mortality and causes of death after multimodality treatment for advanced oral and oropharyngeal cancer. J Oral Maxillofac Surg; 2007 Feb;65(2):255-60
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality and causes of death after multimodality treatment for advanced oral and oropharyngeal cancer.
  • PURPOSE: To analyze mortality and causes of death in patients who received preoperative radiochemotherapy and underwent radical surgery for advanced oral or oropharyngeal cancer.
  • PATIENTS AND METHODS: A total of 222 patients who underwent multimodality treatment from 1990 to 2000 were included in the study.
  • The inclusion criterion was International Union Against Cancer (UICC) disease stage II to IV (T2, 33.3%; T3, 12.6%; T4, 54.1%).
  • Patients received preoperative radiotherapy 50 Gy and concomitant chemotherapy with mitomycin and 5-fluorouracil.
  • Of these, a second cancer in the head and neck region or the lower respiratory tract or the upper digestive tract was found in 7.3%.
  • Although 93% of deaths related to recurrent disease occurred within the first 36 months after surgery, the remaining causes of death did not reveal a specific temporal pattern.
  • CONCLUSION: Favorable survival data were registered for patients with advanced squamous cell carcinoma of the oral cavity who underwent combined treatment protocols.
  • Because recurrent disease is a less common cause of mortality than are other causes, the latter should receive attention during surveillance.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy
  • [MeSH-minor] Cause of Death. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasms, Second Primary / mortality. Oropharyngeal Neoplasms / mortality. Oropharyngeal Neoplasms / surgery. Oropharyngeal Neoplasms / therapy. Radiotherapy, Adjuvant. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236930.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Chambers MS, Mellberg JR, Keene HJ, Bouwsma OJ, Garden AS, Sipos T, Fleming TJ: Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study. Oral Oncol; 2006 Oct;42(9):946-53
Hazardous Substances Data Bank. SODIUM FLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation-induced xerostomia can result in the rapid onset and progression of dental caries in head and neck cancer patients.
  • The intraoral fluoride-releasing system (IFRS) containing a sodium fluoride core is a newly developed, sustained-release, passive drug delivery system that does not require patient involvement except for periodic replacement, thus reducing the effect of patient compliance on its effectiveness in dental caries prevention.
  • Twenty-two head and neck cancer patients from U. T. M. D.
  • Anderson Cancer Center, with radiation-induced xerostomia, were entered into a pilot study to contrast the daily home use of a 0.4% stannous fluoride-gel-containing tray (control group) to IFRS (study group) with respect to tolerability and adherence, and to obtain information on relative caries preventive efficacy.
  • Participants were stratified on the basis of radiation exposure and randomly assigned to treatment with either IFRS or stannous fluoride gel.
  • The efficacy variable was determined by the mean number of new or recurrent decayed surfaces.
  • Patients were examined for caries 4, 8, 12, 24, 36, and 48 weeks after initiation of treatment.
  • No marked differences in follow-up new and recurrent caries were found between the stannous fluoride gel control and IFRS groups during the study period.
  • The rate of new or recurrent carious lesions in the group treated with the fluoride gel was slightly lower than in the IFRS group, based on carious lesions at the baseline examination (Poisson mean number of new or recurrent carious lesions for the control group=0.55 per year vs. 0.83 per year for the study group, p=0.705; odds ratio of the occurrence of any new or recurrent caries during follow-up for control group vs. the study group=0.80; p=0.781).
  • The IFRS is designed to release a daily dose of 0.12mg of sodium fluoride, which can be evenly distributed throughout the oral cavity for a single application of 4 months.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Dental Caries / prevention & control. Sodium Fluoride / administration & dosage. Xerostomia / complications
  • [MeSH-minor] Administration, Topical. Delayed-Action Preparations. Humans. Middle Aged. Mouth Neoplasms / drug therapy. Mouth Neoplasms / microbiology. Mouth Neoplasms / radiotherapy. Pilot Projects. Proportional Hazards Models. Radiotherapy / adverse effects. Streptococcal Infections / complications. Streptococcal Infections / prevention & control. Streptococcus mutans. Tablets. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • MedlinePlus Health Information. consumer health - Tooth Decay.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedIn] Oral Oncol. 2007 Jan;43(1):98-105 [18027401.001]
  • (PMID = 16757200.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Grant] United States / FDA HHS / FD / FD-R-001166-01
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Delayed-Action Preparations; 0 / Tablets; 8ZYQ1474W7 / Sodium Fluoride
  •  go-up   go-down


30. Rigual NR, Thankappan K, Cooper M, Sullivan MA, Dougherty T, Popat SR, Loree TR, Biel MA, Henderson B: Photodynamic therapy for head and neck dysplasia and cancer. Arch Otolaryngol Head Neck Surg; 2009 Aug;135(8):784-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for head and neck dysplasia and cancer.
  • OBJECTIVE: To determine the response of dysplasia, carcinoma in situ (CIS), and T1 carcinoma of the oral cavity and larynx to photodynamic therapy with porfimer sodium.
  • SETTING: A National Cancer Institute-designated cancer institute.
  • PATIENTS: Patients with primary or recurrent moderate to severe oral or laryngeal dysplasia, CIS, or T1N0 carcinoma.
  • INTERVENTION: Porfimer sodium, 2 mg/kg of body weight, was injected intravenously 48 hours before treatment.
  • The light dose was 50 J/cm(2) for dysplasia and CIS and 75 J/cm(2) for carcinoma.
  • Posttreatment biopsies were performed in all patients with persistent and recurrent visible lesions.
  • Three patients with oral dysplasia with an initial CR experienced recurrence in the treatment field.
  • All the patients with NR, a PR, or recurrence after an initial CR underwent salvage treatment.
  • CONCLUSION: Photodynamic therapy with porfimer sodium is an effective treatment alternative, with no permanent sequelae, for oral and laryngeal dysplasia and early carcinoma.
  • [MeSH-major] Carcinoma in Situ / drug therapy. Dihematoporphyrin Ether / administration & dosage. Head and Neck Neoplasms / drug therapy. Low-Level Light Therapy / methods. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage. Precancerous Conditions / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Nov;116(11):1267-70 [2146969.001]
  • [Cites] J Photochem Photobiol B. 1990 Jul;6(3):291-6 [2120406.001]
  • [Cites] Laryngoscope. 1994 Apr;104(4):399-403 [8164476.001]
  • [Cites] Ann Thorac Surg. 1996 Oct;62(4):1005-9; discussion 1009-10 [8823080.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):937-42 [9185692.001]
  • [Cites] Mayo Clin Proc. 1997 Jul;72(7):595-602 [9212759.001]
  • [Cites] Laryngoscope. 1998 Sep;108(9):1259-68 [9738739.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Nov;261(10):534-40 [14714128.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Sep;263(9):843-52 [16823559.001]
  • [Cites] Oncologist. 2006 Oct;11(9):1034-44 [17030646.001]
  • [Cites] Photochem Photobiol. 2007 Sep-Oct;83(5):1063-8 [17880501.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2008 Feb;265(2):189-93 [17962972.001]
  • [Cites] Oral Oncol. 2009 Apr-May;45(4-5):394-401 [18674952.001]
  • [Cites] J Med Assoc Thai. 2000 Mar;83(3):249-58 [10808679.001]
  • [Cites] Laryngoscope. 2001 Jun;111(6):1091-8 [11404627.001]
  • [Cites] J Clin Laser Med Surg. 2002 Feb;20(1):3-7 [11902352.001]
  • [Cites] Head Neck. 2002 Apr;24(4):390-4 [11933181.001]
  • [Cites] Curr Treat Options Oncol. 2002 Feb;3(1):3-9 [12057082.001]
  • [Cites] Int J Oral Maxillofac Surg. 2002 Apr;31(2):145-53 [12102411.001]
  • [Cites] Crit Rev Oral Biol Med. 2003;14(3):199-212 [12799323.001]
  • [Cites] Cancer. 2004 May 1;100(9):1786-92 [15112257.001]
  • [Cites] Int J Oral Maxillofac Surg. 1987 Dec;16(6):656-64 [3125262.001]
  • [Cites] Chin Med J (Engl). 1988 Feb;101(2):86-91 [2970371.001]
  • [Cites] N Engl J Med. 1990 Sep 20;323(12):795-801 [2202902.001]
  • [Cites] Am J Otolaryngol. 1993 Mar-Apr;14(2):116-21 [8484476.001]
  • (PMID = 19687399.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00530088
  • [Grant] United States / NCI NIH HHS / CA / P01 CA055791; United States / NCI NIH HHS / CA / P01 CA055791-16
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  • [Other-IDs] NLM/ NIHMS166203; NLM/ PMC2810853
  •  go-up   go-down


31. Chambers MS, Fleming TJ, Toth BB, Lemon JC, Craven TE, Bouwsma OJ, Garden AS, Espeland MA, Keene HJ, Martin JW, Sipos T: Erratum to "Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study". Oral Oncol; 2007 Jan;43(1):98-105
Hazardous Substances Data Bank. SODIUM FLUORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation-induced xerostomia can result in the rapid onset and progression of dental caries in head and neck cancer patients.
  • The intraoral fluoride-releasing system (IFRS) containing a sodium fluoride core is a newly developed, sustained-release, passive drug delivery system that does not require patient involvement except for periodic replacement, thus reducing the effect of patient compliance on its effectiveness in dental caries prevention.
  • Twenty-two head and neck cancer patients from U. T. M. D.
  • Anderson Cancer Center, with radiation-induced xerostomia, were entered into a pilot study to contrast the daily home use of a 0.4% stannous fluoride-gel-containing tray (control group) to IFRS (study group) with respect to tolerability and adherence, and to obtain information on relative caries preventive efficacy.
  • Participants were stratified on the basis of radiation exposure and randomly assigned to treatment with either IFRS or stannous fluoride gel.
  • The efficacy variable was determined by the mean number of new or recurrent decayed surfaces.
  • Patients were examined for caries 4, 8, 12, 24, 36, and 48 weeks after initiation of treatment.
  • No marked differences in follow-up new and recurrent caries were found between the stannous fluoride gel control and IFRS groups during the study period.
  • The rate of new or recurrent carious lesions in the group treated with the fluoride gel was slightly lower than in the IFRS group, based on carious lesions at the baseline examination (Poisson mean number of new or recurrent carious lesions for the control group=0.55 per year vs. 0.83 per year for the study group, p=0.705; odds ratio of the occurrence of any new or recurrent caries during follow-up for control group vs. the study group=0.80; p=0.781).
  • The IFRS is designed to release a daily dose of 0.12mg of sodium fluoride, which can be evenly distributed throughout the oral cavity for a single application of 4 months.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Dental Caries / prevention & control. Sodium Fluoride / administration & dosage. Xerostomia / complications
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Delayed-Action Preparations. Female. Humans. Male. Middle Aged. Mouth Neoplasms / drug therapy. Mouth Neoplasms / microbiology. Mouth Neoplasms / radiotherapy. Pilot Projects. Proportional Hazards Models. Radiotherapy / adverse effects. Single-Blind Method. Streptococcal Infections / complications. Streptococcal Infections / prevention & control. Streptococcus mutans. Tablets. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • MedlinePlus Health Information. consumer health - Tooth Decay.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RepublishedFrom] Oral Oncol. 2006 Oct;42(9):946-53 [16757200.001]
  • (PMID = 18027401.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Grant] United States / PHS HHS / / FD-R-001166-01/FDA
  • [Publication-type] Clinical Trial, Phase I; Corrected and Republished Article; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Delayed-Action Preparations; 0 / Tablets; 8ZYQ1474W7 / Sodium Fluoride
  •  go-up   go-down


32. Yamaguchi K, Nakagawa S, Yabusaki H, Nashimoto A: [Evaluation of neoadjuvant chemotherapy with paclitaxel, 5-fluorouracil and cisplatin for advanced gastric cancer with pyloric stenosis]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2241-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of neoadjuvant chemotherapy with paclitaxel, 5-fluorouracil and cisplatin for advanced gastric cancer with pyloric stenosis].
  • S-1 is currently recognized as one of the standard treatments for advanced and recurrent gastric cancer in Japan.
  • However, there are some patients who can not take oral medication due to pyloric stenosis.
  • We performed a critical evaluation of neoadjuvant chemotherapy (NAC) with paclitaxel (PTX), 5-fluorouracil (5-FU) and cisplatin (CDDP); (PTX+FP) for patients with advanced gastric cancer with pyloric stenosis.
  • Since September 2001, 13 patients with far advanced or non-curative respectable gastric cancer with pyloric stenosis received NAC.
  • After at least 2 courses of treatment, the patients underwent gastrectomy with lymphadectomy.
  • Seven patients had received staging laparoscopy before NAC and 6 patients had free cancer cells in the peritoneal cavity.
  • Of 6 patients with positive cytology at laparoscopy, 4 had no free cancer cells at operation.
  • In conclusion, combination of PTX+FP for NAC appears to be an effective treatment for patients with advanced gastric cancer with pyloric stenosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pyloric Stenosis / etiology. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Gastrectomy. Humans. Laparoscopy. Lymph Node Excision. Male. Middle Aged. Neoadjuvant Therapy. Paclitaxel / administration & dosage. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079622.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


33. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol; 2010;635:281-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of head and neck cancers.
  • These patients include a mixture of presentations including primary, recurrent, and metastatic lesions.
  • The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma.
  • Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers.
  • Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT.
  • Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment.
  • Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck.
  • It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Photochemotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552353.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin-Harris B, Neville B, Richardson MS, Rosenzweig S, Sharma AK, Smith MM, Stewart S, Stuart RK: Oral cancer treatment. Curr Treat Options Oncol; 2003 Feb;4(1):27-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral cancer treatment.
  • Oral cancer is the sixth most common cancer in the world, and it continues to represent a serious public health problem.
  • Oral cancer is a preventable disease, related to behavioral and lifestyle factors, including tobacco and alcohol.
  • Prevention and early detection of oral cancer remain the goals of national efforts to reduce the impact of this disease on the public.
  • Surgical treatment is the mainstay of therapy for patients with oral cancer, particularly in advanced stages of cancer.
  • External beam radiation therapy and brachytherapy have been used successfully as the primary modality for treating patients with early stage oral cancer, and they are the standard of care for use as adjuvant therapy in postoperative cases of patients with advanced stage oral cancer.
  • There is an emerging trend for the use of chemotherapy in combination with radiation therapy and surgery for patients with advanced, recurrent, and metastatic head and neck cancer, although evidence is limited regarding survival benefit when used for treating patients with oral cavity carcinoma.
  • Any report on the treatment of oral cancer is incomplete without consideration of functional and aesthetic outcomes, particularly addressing speech, swallowing, masticatory efficiency, and dental rehabilitation.
  • Future generations will continue to fight these dreadful diseases until scientists and clinicians are provided the opportunities to expand efforts to prevent, detect (early), and eradicate oral and other head and neck cancers.
  • [MeSH-major] Mouth Neoplasms / surgery
  • [MeSH-minor] Clinical Trials as Topic. Combined Modality Therapy. Diet. Humans. Life Style. Microsurgery. Oral Surgical Procedures

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Laryngoscope. 2002 Jul;112(7 Pt 1):1320-3 [12169922.001]
  • [Cites] Laryngoscope. 1991 Jun;101(6 Pt 1):583-6 [2041436.001]
  • [Cites] Radiother Oncol. 1987 Jan;8(1):11-7 [3809597.001]
  • [Cites] Semin Ultrasound CT MR. 1998 Dec;19(6):463-75 [9861664.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2718-25 [10914716.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]
  • [Cites] J Speech Hear Res. 1993 Oct;36(5):918-26 [8246480.001]
  • [Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]
  • [Cites] J Oral Pathol Med. 2001 Oct;30(9):513-20 [11555152.001]
  • [Cites] Laryngoscope. 1997 Sep;107(9):1239-44 [9292610.001]
  • [Cites] Head Neck. 1991 Sep-Oct;13(5):398-402 [1938355.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jul;128(7):751-8 [12117328.001]
  • [Cites] Radiother Oncol. 2001 Dec;61(3):275-80 [11730997.001]
  • [Cites] Head Neck. 2000 Sep;22(6):559-63 [10941156.001]
  • [Cites] Laryngoscope. 1995 Jul;105(7 Pt 1):669-74 [7603268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Dec;19(6):1369-76 [2262360.001]
  • [Cites] Dysphagia. 1988;3(1):18-23 [3248392.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 May;122(5):662-6 [10793342.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2221-32 [9626224.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6 [10601378.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2065-6 [10601369.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 May;91(5):535-40 [11346731.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jan;128(1):58-62 [11784256.001]
  • [Cites] Am J Surg. 1988 Oct;156(4):286-9 [3177752.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):313-22 [8056575.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Jul;55(7):663-9; discussion 669-71 [9216496.001]
  • [Cites] Head Neck. 2002 Apr;24(4):345-9 [11933176.001]
  • [Cites] Head Neck. 2000 May;22(3):207-14 [10748442.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):605-18 [11309437.001]
  • [Cites] Crit Rev Oral Biol Med. 2001;12(1):55-63 [11349962.001]
  • [Cites] Radiother Oncol. 2000 Jun;55(3):233-9 [11041775.001]
  • [Cites] Nat Med. 2000 Aug;6(8):879-85 [10932224.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):313-7 [9457815.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Dec;125(12):1305-10 [10604407.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1405-10 [11870186.001]
  • [Cites] Ann Oncol. 1992 Aug;3 Suppl 3:11-4 [1390311.001]
  • [Cites] J Am Dent Assoc. 2000 Apr;131(4):453-62 [10770007.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Mar;124(3):348-52 [9525524.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):360-5 [10722009.001]
  • [Cites] Ann Nucl Med. 2001 Dec;15(6):505-12 [11831398.001]
  • [Cites] Cancer. 1972 Jun;29(6):1446-9 [5031238.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):334-42 [11981281.001]
  • [Cites] N Engl J Med. 2001 Apr 26;344(17):1270-8 [11320386.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Jun;18(6):1287-92 [2370178.001]
  • [Cites] Am J Surg. 1993 Oct;166(4):380-3 [8214297.001]
  • [Cites] Community Dent Oral Epidemiol. 2000 Aug;28(4):249-56 [10901403.001]
  • [Cites] Laryngoscope. 1991 Sep;101(9):935-50 [1886442.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] Head Neck. 1997 Jul;19(4):281-6 [9213106.001]
  • [Cites] Head Neck Surg. 1978 Nov-Dec;1(2):107-11 [755803.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Mar;120(3):260-3 [8123233.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):351-6 [9241067.001]
  • [Cites] Head Neck. 1997 Aug;19(5):400-5 [9243267.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3339-45 [11013273.001]
  • [Cites] Gen Dent. 2001 Jan-Feb;49(1):72-82 [12004680.001]
  • [Cites] Head Neck. 2002 Feb;24(2):198-206 [11891950.001]
  • [Cites] Semin Radiat Oncol. 1999 Apr;9(2 Suppl 1):70-6 [10210543.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Cancer Radiother. 1998 Dec;2(6):679-88 [9922773.001]
  • [Cites] CA Cancer J Clin. 2002 Jul-Aug;52(4):195-215 [12139232.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1652-61 [10764425.001]
  • [Cites] Radiology. 1996 Jun;199(3):761-6 [8638002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):705-13 [1618662.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):122-7 [10728605.001]
  • [Cites] Head Neck. 2002 Mar;24(3):262-7 [11891958.001]
  • [Cites] Semin Radiat Oncol. 1998 Oct;8(4):230-6 [9873100.001]
  • [Cites] Head Neck Surg. 1986 Jul-Aug;8(6):401-8 [3721882.001]
  • [Cites] J Speech Hear Res. 1993 Apr;36(2):267-76 [8487519.001]
  • [Cites] Head Neck. 2002 Sep;24(9):841-9 [12211048.001]
  • [Cites] Head Neck. 1996 Mar-Apr;18(2):142-52 [8647680.001]
  • [Cites] Head Neck. 1998 Oct;20(7):588-94 [9744457.001]
  • [Cites] Head Neck. 2002 Feb;24(2):165-80 [11891947.001]
  • [Cites] Nutr Cancer. 1994;21(3):223-32 [8072876.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Aug;84(2):154-7 [9269017.001]
  • [Cites] Am J Surg. 1990 Oct;160(4):410-4 [2221245.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Jun;18(6):1299-306 [2370180.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 May;83(5):537-47 [9159812.001]
  • [Cites] Br J Oral Maxillofac Surg. 1999 Jun;37(3):175-80 [10454023.001]
  • [Cites] Am J Surg. 1986 Oct;152(4):345-50 [3766861.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1996;253(6):329-35 [8858256.001]
  • [Cites] J Speech Lang Hear Res. 2000 Aug;43(4):1011-23 [11386468.001]
  • [Cites] Acta Odontol Scand. 1963 Nov;21:407-14 [14110648.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1998 Apr;124(4):455-9 [9559696.001]
  • [Cites] Oncogene. 2001 Apr 26;20(18):2235-42 [11402318.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):563-8 [6537892.001]
  • [Cites] Cancer Treat Res. 2001;106:221-35 [11225004.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):281-5 [2394607.001]
  • [Cites] J Oral Rehabil. 1992 May;19(3):289-95 [1500972.001]
  • [Cites] Cancer. 1975 Sep;36(3):1021-8 [1182656.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2488-92 [8653682.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jul;177(1):237-43 [11418436.001]
  • [Cites] Oncology (Williston Park). 1990 Oct;4(10):61-9; discussion 72, 76 [2149826.001]
  • [Cites] Head Neck. 2001 Nov;23 (11):979-84 [11754503.001]
  • [Cites] Lancet Oncol. 2001 May;2(5):261-9 [11905780.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Head Neck. 1990 Nov-Dec;12(6):470-5 [2258285.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 May;122(5):517-9 [8615969.001]
  • [Cites] Radiology. 1996 Jul;200(1):135-41 [8657901.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):137-48 [9300748.001]
  • [Cites] Head Neck. 1997 Jan;19(1):14-9 [9030939.001]
  • [Cites] Am J Surg. 2000 Aug;180(2):139-43 [11044531.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):876-83 [10679658.001]
  • [Cites] Cancer Causes Control. 2000 Sep;11(8):713-20 [11065008.001]
  • [Cites] Jpn J Cancer Res. 2000 Oct;91(10):1051-7 [11050477.001]
  • [Cites] J Appl Physiol (1985). 1994 Feb;76(2):714-23 [8175582.001]
  • [Cites] Am J Surg. 1971 Dec;122(6):707-10 [5127723.001]
  • (PMID = 12525277.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 113
  •  go-up   go-down


35. Sudbø J, Lippman SM, Lee JJ, Mao L, Kildal W, Sudbø A, Sagen S, Bryne M, El-Naggar A, Risberg B, Evensen JF, Reith A: The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med; 2004 Apr 1;350(14):1405-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of resection and aneuploidy on mortality in oral leukoplakia.
  • BACKGROUND: Although the standard treatment of oral leukoplakia ranges from watchful waiting to complete resection, the value of these approaches is unknown.
  • METHODS: We studied the relations among resection, ploidy status, and death from cancer in 103 patients with diploid dysplastic oral leukoplakia, 20 patients with tetraploid lesions, and 27 patients with aneuploid lesions.
  • Data on cancer-specific mortality and treatment were obtained from the Cancer Registry of Norway, Statistics Norway, and chart reviews.
  • RESULTS: Primary oral carcinoma developed in 47 of the 150 patients with leukoplakia (31 percent)--5 with diploid, 16 with tetraploid, and 26 with aneuploid leukoplakia--during a mean follow-up of 80 months (range, 4 to 237).
  • The margin status of the initial leukoplakia resection had no relation to the development of oral cancer (P=0.95).
  • Twenty-six of the 47 patients in whom cancer developed (4 with prior tetraploid and 22 with prior aneuploid lesions) had recurrences (55 percent); the recurrences were more frequently multiple and distant (within the oral cavity) among patients with aneuploid lesions than among those with tetraploid or diploid lesions.
  • All 47 patients underwent a standard regimen of surgery and radiation, followed by chemotherapy in the 26 with recurrent cancer.
  • Only patients with aneuploid leukoplakia died of oral cancer; the five-year rate of death from cancer was 72 percent.
  • CONCLUSIONS: Complete resection of aneuploid leukoplakia does not reduce the high risk of aggressive carcinoma and death from oral cancer.
  • [MeSH-major] Aneuploidy. Leukoplakia, Oral / genetics. Leukoplakia, Oral / surgery. Mouth Neoplasms / mortality
  • [MeSH-minor] Aged. Combined Modality Therapy. DNA, Neoplasm. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Leukoplakia.
  • Genetic Alliance. consumer health - Oral leukoplakia.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Massachusetts Medical Society
  • [CommentIn] N Engl J Med. 2006 Feb 9;354(6):638 [16428677.001]
  • [CommentIn] N Engl J Med. 2004 Apr 1;350(14):1382-4 [15070786.001]
  • [CommentIn] N Engl J Med. 2004 Jun 24;350(26):2718-9; author reply 2718-9 [15215492.001]
  • [CommentIn] N Engl J Med. 2004 Jun 24;350(26):2718-9; author reply 2718-9 [15218579.001]
  • [RetractionIn] Curfman GD, Morrissey S, Drazen JM. N Engl J Med. 2006 Nov 2;355(18):1927 [17079770.001]
  • (PMID = 15070790.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


36. Martínez-Monge R, Gómez-Iturriaga A, Cambeiro M, Garrán C, Montesdeoca N, Aristu JJ, Alcalde J: Phase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer. Brachytherapy; 2009 Jan-Mar;8(1):26-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer.
  • BACKGROUND: To determine the feasibility of combined perioperative high-dose-rate brachytherapy (PHDRB) and intermediate-dose external beam radiation therapy (EBRT) as an alternative to full-dose adjuvant EBRT in patients with unirradiated squamous cell cancer (SCC) of the oral cavity and oropharynx.
  • Patients with Stage III, IVa tumors, and some recurrent cases received concomitant cisplatin-paclitaxel chemotherapy during EBRT.
  • Eleven patients (27.5%) developed RTOG Grade 3 or greater toxicity.
  • Four patients (10%) presented complications requiring a major surgical procedure (RTOG 4), and one patient died of bleeding (RTOG 5).
  • Three complications (7.5%) occurred in the perioperative period, and 8 (20.0%) occurred more than 3 months after the completion of the treatment program.
  • CONCLUSIONS: PHDRB can be integrated into the management of patients with resected cancer of the oral cavity who are candidates to receive postoperative radiation or chemoradiation.
  • [MeSH-major] Brachytherapy / adverse effects. Carcinoma, Squamous Cell / radiotherapy. Mouth Neoplasms / radiotherapy. Oropharyngeal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041280.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D; 2007;8(3):176-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
  • Introgen and its wholly owned European subsidiary Gendux AB are developing an adenoviral p53 gene therapy as a treatment for cancer in the US and Europe, respectively.
  • Phase III trials in patients with head and neck cancer are ongoing, and a number of clinical trials in other cancer indications have been completed.
  • INGN 201 is being reviewed by the EMEA for approval in Li-Fraumeni syndrome (LFS) under the provisions of exceptional circumstance; the therapy is available on a compassionate use basis to eligible LFS cancer patients under a protocol authorised by the US FDA.
  • Thus replacing this gene via adenovirally-mediated p53 gene therapy is hoped to result in increased apoptosis where it is administered.INGN 201 is available for licensing, although Introgen favours retaining partial or full rights to the therapy in the US.
  • Introgen entered into a license agreement with The University of Texas System and MD Anderson Cancer Center in 1994.
  • Introgen entered into a collaboration with Rhône-Poulenc Rorer Pharmaceuticals (now sanofi-aventis) to develop therapeutics based on p53 inhibition in October 1994.
  • Introgen initiated two phase III trials in head and neck cancer (in June 2000 and May 2001) at about 80 sites in the US, Canada and Europe; the first is a comparative study of INGN 201 and IV methotrexate in 240 patients with refractory head and neck cancer.
  • The second is for the combination of INGN 201 and standard chemotherapy, compared with standard chemotherapy alone, in 288 patients with recurrent squamous cell carcinoma of the head and neck.
  • Introgen expects to complete regulatory filings for advanced recurrent head and neck cancer in the US and EU within 2007.
  • Favourable phase II data of INGN 201 in a subpopulation of patients with recurrent, unresectable head and neck cancer (SCCHN) prompted Introgen to seek accelerated approval for INGN 201 in December 2004.
  • Introgen had presented combined results from three multicentre (US and Europe) phase II studies of INGN 201 in 217 patients with recurrent squamous cell carcinoma of the head and neck confirming previous safety and efficacy results of the treatment.
  • In April 2004, the Southwest Oncology Group initiated a similar clinical trial using INGN 201 for the treatment of stage III or IV squamous cell carcinoma of the oral cavity, or oropharynx, that is able to be removed surgically.
  • The study assessed the feasibility, efficacy and safety of administering INGN 201 at the time of surgery for suppression of remaining tumour cells, followed by a combination of chemotherapy and radiation therapy.
  • The previous trial was a phase II study that afforded Introgen access to surgical specialists in cancer and complemented the company's ongoing pivotal phase III studies in advanced recurrent disease.
  • Sixty patients with head and neck cancer will undergo surgery at ten US sites and receive INGN 201 intraoperatively (and not postoperatively as used in the former trial) followed by a combination of chemo- and radiotherapy.
  • In September 2003, INGN 201 was granted designation as a Fast Track Drug Product development programme by the FDA for prolonging survival and delaying time to disease progression in patients with recurrent, unresectable squamous cell carcinoma of the head and neck.
  • Previously, in February 2003, INGN 201 received orphan drug designation from the FDA for head and neck cancer.
  • Phase I trials in the US for the treatment of non-small-cell lung cancer have been completed.
  • Sanofi-aventis (formerly Rhône-Poulenc Rorer Gencell) initiated phase II trials in the US, Europe and Canada for non-small-cell lung cancer.
  • Intratumoral injection of RPR/INGN 201 in patients with recurrent glioblastomas was safe and resulted in expression of the p53 protein.
  • Direct administration of RPR/INGN 201 to the lower airways of patients with bronchioalveolar cell lung carcinoma resulted in symptomatic improvement and improved lung function in some patients.
  • In November 2003, according to a Clinical Trials Agreement between the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) and Introgen, a 6-month phase I/II study with p53 gene therapy administered in the form of an oral rinse or mouthwash for patients with oral premalignancies has been initiated.
  • This is the first trial to investigate the effect of this treatment on oral lesions that are at high risk for developing into full blown cancers.
  • In September 2006, the EMEA granted orphan drug status to INGN 201 for the treatment of LFS, following Gendux's application for the designation.
  • The company intends to provide the therapy on a compassionate use basis to qualifying patients in Europe.INGN 201 has been successfully used in the treatment of a LFS patient on a compassionate use basis under a protocol authorised by the FDA.
  • Based on these interim findings, Introgen has decided to continue making the therapy available through a compassionate use programme to eligible LFS patients who have relapsed after standard treatment as part of physician-sponsored protocols at qualifying institutions in the US.A worldwide, exclusive license to a family of US patents covering a combination therapy comprised of INGN 201 in combination with several inhibitors of epidermal growth factor receptors (EGFr) such as Erbituxtrade mark Vectibixtrade mark and Tarcevatrade mark was granted to Introgen by The University of Texas MD Anderson Cancer Center in November 2006.
  • In February 2006, Introgen exclusively licenced a broad patent (US Patent No. 6 989 375), originally issued to to the Board of Regents of The University of Texas System; the patent covers any therapeutic gene-based therapy when applied in combination with conventional cancer therapy such as radiation or chemotherapy.
  • Introgen Therapeutics was awarded a patent from the US Patent and Trademark Office in June 2005 that directly covers many of the special features of its INGN 201 molecular therapy.
  • To date, Introgen controls 30 issued patents relevant to the product covering compositions, therapeutic methods of administering the product in virtually any form, alone and in conjunction with the most widely used chemotherapeutic and radiation treatments, as well as its production, and has a large number of pending patent applications in the US and in foreign countries relating to its ADVEXIN((R)) therapy.
  • Previously, Patent No. 6,805,858 covering methods for the administration of INGN 201 to cancer patients including virtually all of those routes currently being used for adenoviral delivery was awarded.
  • This patent extends Introgen's patent coverage for its adenoviral p53 gene therapy product to the year 2021, not taking into account possible patent extensions.
  • In February 2003, the US Patent and Trademark Office issued patent No. 6,511,847, entitled Recombinant p53 Adenovirus Methods and Compositions, covering any adenoviral DNA molecule that encodes the p53 gene positioned under the control of a promoter.US patents issued in 2002 include Patent No. 6,410,010, broadly covering all adenoviral p53 compositions (including ADVEXIN((R))) that express adequate p53 in amounts sufficient to suppress the growth of or kill cancer cells in patients.
  • The patent also covers adenoviral p53, which incorporates a specific type of promoter that helps cells to express the p53 tumour suppressor gene.
  • Introgen has a number of US patents that relate to the clinical use of adenoviral p53 gene therapy in cancer as monotherapy or in combination with one or more chemotherapeutic drugs, radiation therapies or other agents that have a damaging effect on the DNA or survival of (i.e.
  • 2-methoxyestradiol, Patent No. 6,410,029) cancer cells.A patent with broad claims directed to combination therapy with the p53 gene and conventional chemotherapy or radiation was issued in China in August 2005. Patent No.
  • [MeSH-major] Adenoviridae / genetics. Genes, p53. Genetic Therapy. Neoplasms / therapy. Viral Vaccines / therapeutic use


38. Andreadis C, Vahtsevanos K, Sidiras T, Thomaidis I, Antoniadis K, Mouratidou D: 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer. Oral Oncol; 2003 Jun;39(4):380-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer.
  • The benefit of the effect of chemotherapy in patients with advanced head and neck squamous cell tumors have been demonstrated by recent meta-analyses of randomized studies.
  • However, the role of chemotherapy-especially in advanced oral cancer-is not fully clear, because of the very small amount of phase II literature available.
  • From January 1994 to December 2000, a total of 44 pts aged 33-75 years (mean age 60 years) with advanced and histologically proved squamous cell carcinoma's of the oral cavity received at least one chemotherapy course.
  • The chemotherapy was the initial therapy in a group of 21 patients.
  • In a second group of 23 patients the chemotherapy was delivered after relapse of their disease.
  • The pre-chemotherapy treatment of the second group was radiotherapy in 11, surgery in 4, combination of radiotherapy and surgery in 8 patients.
  • The chemotherapy regimen consisted of cisplatin 100 mg/m(2) in 3-h infusion, day 1 and 5-FU 1000 mg/m(2) in 24-h infusion, days 1-5.
  • Treatment was repeated every 21 days.
  • A total of 154 treatment courses (3.5 per patient, ranged 1-10) were administered.
  • Myelotoxicity, nausea and vomiting were the major treatment complications.
  • The overall response rate to the induction chemotherapy was 52.3%, with 19% complete (CR), and 33.3% partial response's (PR) and to the chemotherapy for recurrent/metastatic disease 30.4% with 8.7% CR, and 21.7% PR.
  • Chemotherapy with cisplatin and 5-FU combination is effective in pts with advanced squamous cell oral cancer and appears to improve the survival of patients who have a good response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Cisplatin / administration & dosage. Cisplatin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Patient Selection. Retrospective Studies. Salvage Therapy. Survival Rate

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Science Ltd.
  • (PMID = 12676258.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


39. Moon C, Chae YK, Lee J: Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med (Maywood); 2010 Aug;235(8):907-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
  • As early detection strategies have not been successful, most patients with head and neck cancer (HNC) present with advanced (stages III and IV) disease.
  • Oral cavity tumors are treated primarily with surgical resection and advanced tumors of the pharynx and larynx are generally treated with combined modality therapy (chemoradiation).
  • The major advances in the management of HNC have evolved from the integration of targeted therapeutics into treatment regimens.
  • Presently, the most important target for new therapeutic strategies in HNC is the epidermal growth factor receptor (EGFR) and so far only cetuximab, a monoclonal antibody targeting EGFR, has been approved by the United States Food and Drug Administration in the HNC population as a radiation-sensitizing agent for patients undergoing primary radiation-based treatment and for patients with recurrent or metastatic disease.
  • The increasing number of molecular targeting strategies in clinical development underscores the need to identify which HNC patients will respond to specific therapies.
  • We hope that this review will provide further insight into the future directions of targeted therapy in the management of advanced HNC.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20562132.001).
  • [ISSN] 1535-3699
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA96784-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  • [Number-of-references] 70
  •  go-up   go-down


40. Toma S, Bonelli L, Sartoris A, Mira E, Antonelli A, Beatrice F, Giordano C, Benazzo M, Caroggio A, Cavalot AL, Gandolfo S, Garozzo A, Margarino G, Schenone G, Spadini N, Sirotovà Z, Zibordi F, Balzarini F, Serafini I, Miani P, Cortesina G: 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep; 2004 Jun;11(6):1297-305
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 13-cis retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group.
  • Patients with squamous cell carcinoma of the head and neck (HNSCC) after being treated radically remain at high risk for both recurrent and second primary tumours.
  • 13-cis retinoic acid (13-cRA) was demonstrated to reverse pre-malignant lesions of the oral cavity and to reduce the incidence of second primary tumours in patients treated radically for HNSCC.
  • From February 1992 to January 1996, 267 patients were randomized: 126 were allocated to the control group, 126 were randomized to receive 13-cRA at a dose of 0.5 mg/kg per day per os and 15 patients have been assigned to the group of 13-cRA plus interferon alpha2a (IFN-alpha2a) at a dose of 3,000,000 UI 3 times a week (randomization in this arm interrupted due to administrative financial problems).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Interferon-alpha / therapeutic use. Isotretinoin / therapeutic use
  • [MeSH-minor] Adult. Aged. Chemoprevention. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15138569.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; EH28UP18IF / Isotretinoin
  •  go-up   go-down


41. Kübler AC, de Carpentier J, Hopper C, Leonard AG, Putnam G: Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy. Int J Oral Maxillofac Surg; 2001 Dec;30(6):504-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of squamous cell carcinoma of the lip using Foscan-mediated photodynamic therapy.
  • Carcinoma of the lip is a common cancer of the head and neck area; its incidence is approximately one-quarter that for oral cavity cancers.
  • This non-randomized Phase II study aimed to estimate the complete response (CR) rate to Foscan-mediated photodynamic therapy (Foscan-PDT) in patients with primary cancer of the lip, duration of CR, and the tolerability and safety of Foscan-PDT.
  • Twenty-five patients with squamous cell carcinoma (SCC) of the lip (Tis, T1, T2/N0/M0) and Karnofsky status > or = 70 received 0.15 mg/kg Foscan intravenously, followed 4 days later by a single non-thermal illumination of the tumour (light dose 20 J/cm2, irradiance 100 mW/cm2, lambda=652 nm).
  • The most common adverse event was swelling and local pain at the treatment site.
  • One patient developed a single lymph node metastasis 7 months after therapy.
  • The functional results were excellent in all patients without any signs of limited mouth opening or impaired lip closure.
  • The cosmetic outcome was better than after surgical therapy.
  • Foscan-PDT is an effective treatment modality for small primary tumours of the lips.
  • It allows preservation of form and function and does not compromise future treatment options for recurrent, residual or second primary disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Lip Neoplasms / drug therapy. Mesoporphyrins / therapeutic use. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Follow-Up Studies. Humans. Injections, Intravenous. Laser Therapy. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Photosensitivity Disorders / chemically induced. Prospective Studies. Radiation Dosage. Remission Induction. Safety. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11829232.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


42. Warde P, Kroll B, O'Sullivan B, Aslanidis J, Tew-George E, Waldron J, Maxymiw W, Liu FF, Payne D, Cummings B: A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer; 2000 May;8(3):203-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer.
  • One of the major side effects of radical radiation therapy for head and neck malignancies is xerostomia, or dryness of the mouth.
  • There is no clearly effective treatment for this condition, but we have observed that patients in our practice believe that their symptoms improve significantly when using two "over-the-counter" oral comfort products - Biotene (toothpaste, mouthwash and chewing gum) and Oralbalance gel.
  • All had biopsy-proven carcinoma of the nasopharynx, oropharynx, oral cavity, hypopharynx or larynx, and had received primary radiotherapy with curative intent (> or =50 Gy in 20 fractions) more than 4 months before study entry.
  • There was no clinical evidence of recurrent disease.
  • Patients with an increase of 10 mm from their baseline score on the visual analogue scale were classified as having responded to the treatment intervention, and those with an increase of > or =25 mm from their baseline score were classified as having experienced a major improvement in their symptoms.
  • After 2 months of treatment, 15 patients (54%) reported an improvement in intraoral dryness and 10 of these patients (36%) reported a major improvement.
  • Seventeen patients (61%) reported an improvement in oral discomfort, and 12 of these (43%) had a major improvement in their symptoms.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Glucose Oxidase / therapeutic use. Head and Neck Neoplasms / radiotherapy. Lactoperoxidase / therapeutic use. Muramidase / therapeutic use. Xerostomia / drug therapy. Xerostomia / etiology
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Drug Combinations. Female. Humans. Male. Middle Aged. Radiotherapy / adverse effects. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dry Mouth.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10789961.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Biotene; 0 / Drug Combinations; EC 1.1.3.4 / Glucose Oxidase; EC 1.11.1.- / Lactoperoxidase; EC 3.2.1.17 / Muramidase
  •  go-up   go-down






Advertisement